By Stephen Nakrosis
Biotech company Polyrizon Ltd. filed for an initial public offering with the U.S. Securities and Exchange Commission on Wednesday.
The company said it plans to offer units in its IPO, which will consist of one ordinary share and two warrants, each for the purpose of buying one ordinary share. The company didn't give an expected size for its IPO, nor did it provide an anticipated price range.
The company said it is developing medical device hydrogels delivered in the form of nasal sprays that can provide a barrier against viruses and allergens.
Polyrizon, which has headquarters in Israel, said it applied to list its shares and warrants on the Nasdaq Capital Market.
Aegis Capital Corp. is listed as the offering's sole book-running manager.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
